MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer

Published:2019-10 Issue: Volume:30 Page:v856
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Sledge G.W.,Toi M.,Neven P.,Sohn J.,Inoue K.,Pivot X.,Burdaeva O.,Okera M.,Masuda N.,Kaufman P.A.,Koh H.,Grischke E.-M.,Conte P.F.,Lu Y.,Barriga S.,Hurt K.,Frenzel M.,Johnston S.R.D.,Llombart-Cussac A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer;Cancers;2023-10-02

2. Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors;Future Oncology;2023-07

3. Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor;Cancer Communications;2023-04-26

4. Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer;The Oncologist;2023-03-22

5. Patient preferences do matter: a discrete choice experiment conducted with breast cancer patients in six European countries, with latent class analysis;International Journal of Technology Assessment in Health Care;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP